Mitochondria-derived Vesicle Packaging as a Novel Therapeutic Mechanism in Pulmonary Hypertension

Qiang Zhao1,2, Zhixue Liu1, Ping Song1

  • 1Center for Molecular and Translational Medicine, Georgia State University, Atlanta, Georgia; and.

Insights

Defects in mitochondria-derived vesicles (MDVs) shedding, regulated by liver kinase B1 (LKB1), cause pulmonary hypertension (PH) by impairing mitochondrial function in pulmonary endothelial cells (ECs). Restoring LKB1 function reversed PH in rats.

Area of Science:

  • Mitochondrial Biology
  • Cellular Physiology
  • Vascular Biology

Background:

  • Mitochondrial dysfunction in pulmonary endothelial cells (ECs) is implicated in pulmonary hypertension (PH).
  • The precise mechanisms leading to mitochondrial dysfunction in PH remain unclear.
  • Mitochondria-derived vesicles (MDVs) are involved in mitochondrial quality control, but their role in PH is unknown.

Purpose of the Study:

  • To investigate the regulation of MDV shedding in pulmonary ECs.
  • To determine if MDV deregulation contributes to mitochondrial dysfunction and PH.
  • To elucidate the role of liver kinase B1 (LKB1) in MDV shedding and PH pathogenesis.

Main Methods:

  • Examined MDV formation and mitochondrial morphology/dynamics in LKB1-deficient ECs, PH rat models, and human PH lung tissues.
  • Assessed mitochondrial ultrastructure, MDV shedding, and Rab9 GTPase localization.
  • Utilized adeno-associated virus (AAV)-LKB1 gene therapy in a rat model of PH.

Main Results:

  • Pulmonary ECs from PH patients and hypoxia-treated cells showed increased mitochondrial fragmentation and defective MDV shedding.
  • LKB1 deficiency in ECs led to spontaneous PH, impaired MDV shedding, and disrupted mitochondrial dynamics.
  • LKB1-mediated recruitment of Rab9 GTPase to mitochondria is essential for MDV shedding.
  • AAV-LKB1 treatment reversed PH in rats, improving MDV shedding and mitochondrial function.

Conclusions:

  • LKB1 regulates MDV shedding from pulmonary ECs by promoting Rab9 GTPase mitochondrial recruitment.
  • Defective LKB1-mediated MDV shedding contributes to EC dysfunction and PH development.
  • Targeting LKB1-MDV pathway may offer a therapeutic strategy for PH.

Related Concept Videos

Pulmonary Hypertension: Classification and Pathogenesis01:30

Pulmonary Hypertension: Classification and Pathogenesis

Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
216
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
197
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
199
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
210
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure01:16

Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure

Oxygen therapy has emerged as a significant tool in enhancing the quality of life for patients suffering from pulmonary arterial hypertension (PAH). While this therapy has principally been studied on patients with significant hypoxemia, this therapeutic approach helps prevent potential organ damage and can be administered in the comfort of one's home.
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
256
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors01:28

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
183